1 / 46

Chronic Kidney Disease

Chronic Kidney Disease. Dr Dana Ahmed Sharif MRCP UK/ MRCP London. Each kidney has: a renal artery a renal vein a ureter which enter the kidney at the hilum. The kidney has: an outer cortex layer an inner medullary pyramid layer fine branches of the ureter which form the calyx.

yuma
Télécharger la présentation

Chronic Kidney Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chronic Kidney Disease Dr Dana Ahmed Sharif MRCP UK/ MRCP London

  2. Each kidney has: • a renal artery • a renal vein • a ureter • which enter the kidney at the hilum. • The kidney has: • an outer cortex layer • an inner medullary pyramid layer • fine branches of the ureter which form the calyx

  3. The NEPHRON is the functional unit of the kidney. Each kidney has nearly a million of nephrons Each nephron: is supplied with an afferent arteriole. produces urine which drains into a collecting duct. The collecting ducts fuse together to make larger and larger tubes until they join together as the ureter Each nephron consists of: a glomerulus & Bowman’s capsule a proximal convoluted tubule a loop of Henle a distal convoluted tubule

  4. Chronic Kidney Disease • Longstanding and irreversible decline in renal function • Injured nephrons replaced by extensive fibrosis • Normal nephrons gradually fail due to ‘hyperfilteration’ • Is mainly TUBULAR scarring, so urine output usually normal, though urine quality reduced • Any cause of AKI can eventually lead to CKD

  5. Assessment of renal function • 60 years old woman - Creatinine 1.1 (0.4-1.1mg/dl) - Wt 48 Kg • 20 years old man - Creatinine 1.3 (0.7-1.2mg/dl) - Wt 98 Kg

  6. How do we assess renal function? • Serum urea and creatinine - Small molecules - Filtered by glomerulus – measure of GFR - But creatinine also depends on: + Muscle mass + Body size + Sex and race • Measurement of GFR - Direct measurement - Estimation of GFR (eGFR)

  7. Shenmesh, O., Golbetz, H., Kriss, J. P., and Myers, B. D. (1985). Kidney International 28 , 830–838

  8. Staging of chronic kidney diseaseK/DOQI guideline *Only considered to be CKD stage 1 or 2 if proteinuria and/or haematuria or structural renal disease are present

  9. CKD prevalence Stage 5: 0.2% Stage 4: 0.2% Stage 3: 4.3% Stage 2: 3.0%% Stage 1: 3.3% Coresh J. Astor BC, Greene T, et al. (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Study. Am J Kidney Dis, 41(1), 1-12

  10. Why is it important to identify patients with CKD? • CKD predispose to increased cardiovascular risk (modify risk factors such as Hypertension) • Some patient may benefit from other investigations ( such as renal biopsy) • It may be possible to slow down the progression • Complications of CKD can be identified and treated early • Preparation for dialysis or transplantation once they reach end-stage.

  11. ?Acute or Chronic kidney impairment • History and duration of symptoms • Previous urinalysis or measurement of renal function • Rapid changes in renal function • Normocytic, normochromic anaemia( but haemorrhage, haemolysis) • Ultrasound: small kidneys and increased echogenicity • Evidence of renal osteodystrophy ( ie digital subperiosteal erosions)

  12. Who is at risk? • Known CKD • Hypertension • Diabetes • Unexplained oedema • Congestive cardiac failure • Atherosclerotic disease ( coronary, cerebral, peripheral) • Multi systemic disease ( myeloma, SLE) • Bladder outflow obstruction, neurogenic bladder, renal stone disease, recurrent UTI • Chronic nephrotoxic use ( NSAID, ACEI, ARBII, ciclosporin, lithium) • Urologically unexplained haematuria

  13. Why chronic renal failure tends to progress? • Once CKD established, inexorable progression is likely • While only 10% of those with CKD stage 3 may progress, all are at risk • Therefore life-long follow up is desirable

  14. Mechanism of progression • Raisedintraglomerular pressure • Glomerular damage • Proteinuria • Tubulo-intestitial scarring

  15. Importance of proteinuria • Normal glomeruli do not leak protein • Proteinuria is a sign of glomerular dysfunction • Proteinuria is also risk factor for progression of CKD

  16. Importance of proteinuria • Normal glomeruli do not leak protein • Proteinuria is a sign of glomerular dysfunction • Proteinuria is also risk factor for progression of CKD • Measures which reduce proteinuria slow down the progression of CKD* • Albuminuria is a marker of cardiovascualr risk** *GISEN Group (1997). Lancet 349 , 1857–1863 **Hebert, L. A., Spetie, D. N., and Keane, W. F. (2002). Postgraduate Medicine 111 , 23.

  17. Causes of End Stage Renal Disease* • Diabetes • Glomerulonephritis • Reflux nephropathy • Renovascular disease • Hypertension • Polycystic kidney disease *UK renal data registry

  18. Case 1 • 55 years old male • History of diabetes for 15 years • He has CKD with eGFR 35ml/min( checked 6 months ago). • His BP was 140/90 and his doctor started him on Ramipril 2.5 mg two weeks ago. • Lab results: eGFR of 25ml/min otherwise well, HbA1c 6.0%, urinary protein excretion of 0.5g/24hrs( no changes from previous results).

  19. What is the most likely cause of his renal deterioration? 1- Progression of his diabetic nephropathy 2- Uncontrolled hypertension 3- Infection 4- Drug induced

  20. What is the most likely cause of his renal deterioration? 1- Progression of his diabetic nephropathy 2- Uncontrolled hypertension 3- Infection 4- Drug induced

  21. Reversible causes of deteriorating renal function • Blood pressure control • Diabetes control • Obstruction • Drug, contrast agent • Intercurrent illness • Exacerbation of underlying kidney disease (sarcoidosis, lupus)

  22. Preventing progression • Blood pressure and diabetes - Uncontrolled Hypertension and diabetes makes proteinuria worse - Controlling hypertension and diabetes is vital • ACE inhibitors and ARBs have anti-proteinuric effects over and above their effects via blood pressure - Agents of choice in proteinuric renal disease - Even if blood pressure ‘normal’

  23. Blood pressure targets* • CKD with no proteinuria: <140/90 mmHg • CKD with proteinuria: <130/80 mmHg • Diabetic nephropathy: <130/80mmHg (aim for 125/75 mmHg). * NICE guideline for management of Chronic Kidney Disease, Sept 2008

  24. Managing CKD 1- General advice: • Smoking cessation • Weight reduction if obese • Encourage aerobic exercise • Aspirin 75mg od ( if 10 years cardiovascular risk>20%) • Treat hyperlipidaemia • Avoid NSAID and other nephrotoxic drugs • Limit alcohol intake( <21units/wk in male, <14units/wk in female • Vaccination against influenza and pneumococcus

  25. Managing CKD 2- CKD stages 1-3: • Monitor eGFR, urinalysis and protein creatinine ratio • Meticulous BP and diabetes control • If Hb < 11g/dl check ferritin, B12 and folate( if ferritin <100mg/dl start on oral or IV iron) • Annual check of PTH, Calcium and phosphate

  26. Managing CKD 3- CKD stages 4-5: • Refer to nephrologist • Full dietary assessment • Optimize PTH, Calcium and phosphate • Correct acidosis • Hepatitis B immunization • Discuss future treatment (dialysis, transplant or conservative/palliative)

  27. Complications of CKD • Uraemia • Anaemia • Renal bone disease • Salt and water retention • Electrolyte imbalance • Acidosis • Cardiovascular disease and lipids

  28. Salt and water retention • Dietary salt restriction ( aim <5g/day) • Fluid intake restriction • Diuretics such as furosemide, titrate up • Add thiazide ( metolazone) • Those with fluid overload and on diuretics monitor: - Weight ( loss of 1kg/day) - BP control - Monitor electrolyte - if Ur > 70mg/dl consider reducing diuretics - Refractory volume overload = dialysis

  29. Hyperkalaemia • Common and potentially fatal • Rapid rise of K+ is more dangerous than gradual ones, as cell membrane stability is more vulnerable to acute changes • ↑K+ → depolarization of the membrane resting potential → Na+ channel inactivation → ↓membrane excitability → neuromuscular depression and cardiac dysrhythmias. • When to treat: • K+: 5.5-6.0 mmol/l: recheck routinely. Review medications and arrange dietary advice • K+: 6.1-6.5 mmol/l: recheck urgently, review med, stop ACEI/ARB2 and arrange dietary advice. • K+: >6.5 mmol/l: admit for emergency management

  30. Measures to prevent ↑K+ - Dietary restriction: diary products, potatoes and some fruits (such as banana ,grapes, pineapple), fresh fruit juice, tomatoes, sweet corn, mushrooms, chocolate and coffee. - Loop diuretics: promote urinary K+ excretion. - Drug withdrawal or dose reduction (ACEI, ARB2), review other contributory drugs (spironolactone, NSAID and B- blockers) - Correct acidosis. - Dialysis ( especially in refractory ↑K+)

  31. Acidosis Leads to: • Bone: increase bone resorption and impaired mineralization, contributing to renal osteodystrophy. • Over ventilation (compensatory mechanism) • Hyperkalaemia • Increased ionized Calcium (acidosis lead to reduced albumin bound fraction) • Malnutrition: acidosis promotes catabolism

  32. How to correct acidosis? • Treat when venous HCO3- is <21 mmol/l • Give NaHCO3 tablet 0.5-1.5g/tds • Refractory acidosis: dialysis

  33. Uraemia • Clinical syndrome caused by substantial fall in GFR • Failure to eliminate potentially toxic small and middle size molecules. • NOT a result of high blood urea concentration. • Ur and Cr are not directly toxic. • Leads to: - Chronic inflammation and ↑oxidative stress - Accumulation of metabolic end products - Accelerated atherogenesis - Disruption of immune system - phosphate is retained: leads to ↑PTH, arteriosclerosis and vascular calcification

  34. Uraemia Symptoms: • Nausea/ vomiting • Anorexia and weight loss • Malaise, fatigue • Confusion, fits and coma • Pericarditis

  35. Anaemia • Erythropoietin(EPO) is essential for the terminal maturation of erythrocyte • EPO deficiency occur in most advanced CKD ( eGFR < 35ml/min) with exception: - Adult polycystic kidney disease - Benign renal cysts - Renal cell carcinoma

  36. Differential diagnosis of anaemia in CKD • EPO deficiency • Iron deficiency anaemia • Blood loss ( GI tract, Haemodialysis) • Folate deficiency • B12 deficiency • Haemolysis • Myelodyplasia • Myeloma

  37. Case 2 • 54 years old male with CKD stage 4 • History or recurrent chest infection for the last 3months • On oral co-amoxiclav, Erythropoietin injection 6000 iu sc weekly( increased recently) • Lab results: Hb 8.5g/dl(no changes), WBC: 14, eGFR:16, CRP:75, ferritin: 600

  38. What is the most likely cause of EPO non-responsiveness 1- Non-compliance 2- Inadequate dose of EPO 3- High CRP 4- Iron deficiency anaemia

  39. What is the most likely cause of EPO non-responsiveness 1- Non-compliance 2- Inadequate dose of EPO 3- High CRP 4- Iron deficiency anaemia

  40. EPO non-response • Iron deficiency • Chronic blood loss • Infection/inflammation • Severe hyperparathyroidism (causes bone marrow fibrosis) • B12 and folate deficiency • Haemolysis • Malnutrition • Inadequate dosing • Poor compliance

  41. Renal bone disease (Osteodystrophy) • Heterogeneous disorder leading to diminished bone strength • Is a function of bone turnover, density, mineralization and architecture • Mostly occur beyond CKD stage 3 • High turnover( PTH > 450ng/L*) : caused by secondary hyperparathyroidism leads to increased bone resorption and formation(osteitisfibrosacystica) • Low turnover (Adynamic bone disease)( PTH < 100ng/L): paucity of cells with decreased bone resorption and formation. • Osteomalacia: defect in mineralization, deficiency of 1,25(OH)2D • Osteoporosis: reduced bone density

  42. Renal bone disease: clinical features 1- Secondary hyperparathyroidism: • Usually asymptomatic • Bone pain and arthralgia • Muscle weakness • Pruritis (cutaneous calcium phosphate deposition) • Bone deformity • Increased fracture risks (hip fracture x5 in Dialysis) • Marrow fibrosis contribute to anaemia 2- Adynamic bone disorder: asymptomatic and may have twice increase in fracture risk than dynamic bone disease. 3- Increased cardiovascular risk

  43. Renal bone disease: treatment • Measures to reduce serum phosphate: - Dietary PO4 restriction( meat, egg, milk, cereals) - Dialysis - Oral phosphate binders( prevent absorption)such as Ca+2 and non-Ca+2 containing phosphate binder • Measures to increase serum calcium and suppress PTH: - Ca+2 salts ( also act as PO4 binder) - Vit D analogues (calciterol, alfacalcidol) • Measures to suppress PTH directly: - Calcimimetic agents(cinacalcet) - Parathyroidectomy( tertiary PTH= PTH, Ca2,PO4 and ALP)

  44. Malnutrition Causes: • Anorexic uraemic toxins(↑leptin) • Chronic low grade inflammation and oxidative stress. • Dietary restriction (low protein diet) • Medications (iron, PO4 binders) • Acidosis • Dialysis itself (protein loss during dialysis) • Biochemical indicators: s. albumin, transferrin and cholesterol

More Related